Vivien Beyersdorfer

Vivien Beyersdorfer

Auto-generated profile, based on publicly available information

Vivien Beyersdorfer

Department of Biomedicine, University of Basel, Basel, Switzerland, Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg Eppendorf, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
DEDesalegn Tadesse Egu
Desalegn Tadesse Egu
TSThomas Schmitt
Thomas Schmitt
NENancy Ernst
Nancy Ernst
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig
MFMichael Fuchs
Michael Fuchs
JWJens Waschke
Jens Waschke
Pemphigus is a severe blistering disease caused by autoantibodies primarily against the desmosomal cadherins desmoglein (DSG)1 and DSG3 which impair desmosome integrity. Especially for the acute phase, additional treatment options allowing to reduce corticosteroids would fulfill an unmet medical need. Here, we provide evidence that epidermal growth factor receptor (EGFR) inhibition by erlotinib ameliorates pemphigus vulgaris immunoglobulin G (PV-IgG) -induced acantholysis in intact human epidermis. PV-IgG caused phosphorylation of EGFR (Y845) and SRC in human epidermis. In line with that, a phosphotyrosine kinome analysis revealed a robust response associated with EGFR and SRC family kinase signaling in response to PV-IgG but not pemphigus foliaceus autoantibodies. Erlotinib inhibited PV-IgG-induced epidermal blistering and EGFR phosphorylation, loss of desmosomes as well as ultrastructural alterations of desmosome size, plaque symmetry, keratin filament insertion and restored the desmosome midline considered as hallmark of mature desmosomes. Erlotinib enhanced both single molecule DSG3 binding frequency and strength and delayed DSG3 fluorescence recovery supporting that EGFR inhibition increases DSG3 availability and cytoskeletal anchorage. Our data indicate that EGFR is a promising target for pemphigus therapy due to its link to several signaling pathways known to be involved in pemphigus pathogenesis.

13 March 2024 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
MRMaitreyi Rathod
Maitreyi Rathod
HFHenriette Franz
Henriette Franz
VBVivien Beyersdorfer
Vivien Beyersdorfer
MWMarie-Therès Wanuske
Marie-Therès Wanuske
KLKaren Leal-Fischer
Karen Leal-Fischer
VSVolker Spindler
Volker Spindler
Glycosylation is essential to facilitate cell–cell adhesion and differentiation. We determined the role of the dolichol phosphate mannosyltransferase (DPM) complex, a central regulator for glycosylation, for desmosomal adhesive function and epidermal differentiation. Deletion of the key molecule of the DPM complex, DPM1, in human keratinocytes resulted in weakened cell–cell adhesion, impaired localization of the desmosomal components desmoplakin and desmoglein-2, and led to cytoskeletal organization defects in human keratinocytes. In a 3D organotypic human epidermis model, loss of DPM1 caused impaired differentiation with abnormally increased cornification, reduced thickness of non-corneal layers, and formation of intercellular gaps in the epidermis. Using proteomic approaches, SERPINB5 was identified as a DPM1-dependent interaction partner of desmoplakin. Mechanistically, SERPINB5 reduced desmoplakin phosphorylation at serine 176, which was required for strong intercellular adhesion. These results uncover a novel role of the DPM complex in connecting desmosomal adhesion with epidermal differentiation.